Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-224-1000
Debt
Current Ratio12.19
Quick Ratio11.88
Price-To-Earnings
Sales & Book Value
Annual Sales$4.60 million
Price / Sales28.22
Price / Cash FlowN/A
Price / Book2.80
Profitability
Net Income$-34,800,000.00
Net Margins-732.47%
Return on Assets-59.65%
Miscellaneous
Employees75
OptionableOptionable
Organovo (NASDAQ:ONVO) Frequently Asked Questions
What is Organovo's stock symbol?
Organovo trades on the NASDAQ under the ticker symbol "ONVO."
How were Organovo's earnings last quarter?
Organovo Holdings Inc (NASDAQ:ONVO) posted its earnings results on Thursday, November, 8th. The medical research company reported ($0.05) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.03. The medical research company earned $0.94 million during the quarter, compared to analysts' expectations of $0.90 million. Organovo had a negative net margin of 732.47% and a negative return on equity of 65.73%. View Organovo's Earnings History.
When is Organovo's next earnings date?
What price target have analysts set for ONVO?
2 brokers have issued 1 year target prices for Organovo's stock. Their forecasts range from $1.75 to $2.50. On average, they expect Organovo's share price to reach $2.1250 in the next twelve months. This suggests a possible upside of 89.7% from the stock's current price. View Analyst Price Targets for Organovo.
What is the consensus analysts' recommendation for Organovo?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Organovo.
Has Organovo been receiving favorable news coverage?
News stories about ONVO stock have been trending positive on Thursday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Organovo earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days.
Who are some of Organovo's key competitors?
Some companies that are related to Organovo include DBV TECHNOLOGIE/S (DBVT), PDL BioPharma (PDLI), Mesoblast (MESO), Scholar Rock (SRRK), Agenus (AGEN), Krystal Biotech (KRYS), CASI Pharmaceuticals (CASI), Nightstar Therapeutics (NITE), Avrobio (AVRO), Replimune Group (REPL), Cellular Biomedicine Group (CBMG), MeiraGTx (MGTX), Voyager Therapeutics (VYGR), Gamida Cell (GMDA) and Translate Bio (TBIO).
Who are Organovo's key executives?
Organovo's management team includes the folowing people:
- Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
- Mr. Craig Kussman, Chief Financial Officer (Age 60)
- Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
- Mr. Paul Gallant, Gen. Mang. (Age 54)
- Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications
How do I buy shares of Organovo?
Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Organovo's stock price today?
One share of ONVO stock can currently be purchased for approximately $1.12.
How big of a company is Organovo?
Organovo has a market capitalization of $120.53 million and generates $4.60 million in revenue each year. The medical research company earns $-34,800,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Organovo employs 75 workers across the globe.
What is Organovo's official website?
How can I contact Organovo?
Organovo's mailing address is 6275 NANCY RIDGE DRIVE SUITE 110, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]
MarketBeat Community Rating for Organovo (NASDAQ ONVO)
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
